Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials-Reference-Cited by-同舟云学术

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Published:2020-07 Issue:1 Volume:73 Page:26-39
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Harrison Stephen A.,Wong Vincent Wai-Sun,Okanoue Takeshi,Bzowej Natalie,Vuppalanchi Raj,Younes Ziad,Kohli Anita,Sarin Shiv,Caldwell Stephen H.,Alkhouri Naim,Shiffman Mitchell L.,Camargo Marianne,Li Georgia,Kersey Kathryn,Jia Catherine,Zhu Yanni,Djedjos C. Stephen,Subramanian G. Mani,Myers Robert P.,Gunn Nadege,Sheikh Aasim,Anstee Quentin M.,Romero-Gomez Manuel,Trauner Michael,Goodman Zachary,Lawitz Eric J.,Younossi Zobair

Funder

Gilead Sciences

Publisher

Elsevier BV

Subject

Hepatology

Reference24 articles.

1. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

2. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data;Kabbany;Am J Gastroenterol,2017

3. Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand;Calzadilla-Bertot;Liver Transpl,2019

4. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States;Wong;Gastroenterology,2015

5. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances;Noureddin;Am J Gastroenterol,2018

Cited by 328 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

2. Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches;Cureus;2024-09-10

3. Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?;Digestive and Liver Disease;2024-09

4. Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression;Journal of Hepatology;2024-09

5. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09